Shuttle Pharmaceuticals Holdings (SHPH) Income from Continuing Operations (2021 - 2026)
Shuttle Pharmaceuticals Holdings' (SHPH) quarterly Income from Continuing Operations came in at 2516613.0 in Q1 2026, up 20.14% year-on-year from 2094751.32 in Q1 2025, and up 9.72% quarter-over-quarter from 2787712.0 in Q4 2025.
Shuttle Pharmaceuticals Holdings (SHPH) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Shuttle Pharmaceuticals Holdings' Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 2516613.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 20.14% year-over-year to 2516613.0 in Q1 2026; TTM through Mar 2026 was 11894104.0, a 18.87% decrease from a year earlier, with the FY2025 full-year figure at 19701474.0, down 54.97% from the prior year.
- Income from Continuing Operations rose to 2516613.0 in Q1 2026 per SHPH's latest filing, from 2787712.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 368462.0 in Q2 2022 and bottomed at 4223323.0 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 1995490.0 (2023), against an average of 2086797.41.
- Across the five-year window, Income from Continuing Operations slumped 492.21% in 2022 and advanced 27.16% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 2718530.0 in 2022, then advanced by 19.01% to 2201872.0 in 2023, then climbed by 22.51% to 1706135.0 in 2024, then sank by 63.39% to 2787712.0 in 2025, then climbed by 9.72% to 2516613.0 in 2026.
- Per Business Quant, the three latest SHPH Income from Continuing Operations figures stand at 2516613.0 (Q1 2026), 2787712.0 (Q4 2025), and 2366456.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Shuttle Pharmaceuticals Holdings | 120,186.04 | 120,186.04 | - | -2.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.52 Mn |
| Dec 31, 2025 | -2.79 Mn |
| Sep 30, 2025 | -2.37 Mn |
| Jun 30, 2025 | -4.22 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | -1.71 Mn |
| Sep 30, 2024 | -3.25 Mn |
| Jun 30, 2024 | -1.90 Mn |
| Mar 31, 2024 | -1.86 Mn |
| Dec 31, 2023 | -2.20 Mn |
| Sep 30, 2023 | -1.78 Mn |
| Jun 30, 2023 | -2.00 Mn |
| Mar 31, 2023 | -975,097.00 |
| Dec 31, 2022 | -2.72 Mn |
| Sep 30, 2022 | -998,425.00 |
| Jun 30, 2022 | -368,462.00 |
| Mar 31, 2022 | -681,839.00 |
| Dec 31, 2021 | -459,048.00 |
| Sep 30, 2021 | -216,961.00 |